期刊文献+

CYP3A5基因多态性与临床合理用药 被引量:6

下载PDF
导出
摘要 目的阐明CYP3A5基因多态性对药物代谢的影响,以指导临床合理用药。方法查阅相关文献,对CYP3A5基因代谢的药物进行分析归纳。结果 CYP3A5基因多态性与调血脂药、抗癫痫药、抗精神病药、抗癌药、免疫抑制剂等多种临床药物的疗效及不良反应相关。结论应重视CYP3A5基因分型,以指导临床个体化合理用药。
作者 丁晴 冯端浩
出处 《解放军药学学报》 CAS CSCD 2015年第5期435-438,共4页 Pharmaceutical Journal of Chinese People's Liberation Army
  • 相关文献

参考文献10

  • 1Kolovou G,Ragia G,Kolovou V,et al.Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin. Open Cardiovasc Med J . 2014
  • 2Wang Y,Wang M,Qi H,et al.Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials. Drug Metabolism and Disposition . 2014
  • 3Joseph P,Kitzmiller,Jasmine A.et al.CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenet Genomics . 2014
  • 4Rojas L,Neumann I,Herrero MJ,et al.Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus:a systematic review and meta-analysis of observational studies. Pharmacogenomics . 2015
  • 5Merck Sharp & Dohme Corp.Simvastatin prescribing information. . 1999-2014
  • 6Tanno L,Kerr D,Santos B,et al.Polymorfism Of CYP2C9 And3A5 and carbamazepine hypersensitivity reactions in Brazilian subjects. Clin Transl Allergy . 2014
  • 7de Graan AJ,Elens L,Sprowl JA,et al.CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clinical Cancer Research . 2013
  • 8Apellániz-Ruiz M,Lee MY,Sánchez-Barroso L,et al.Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy. Clinical Cancer Research . 2015
  • 9Suarez-Kurtz G,Vargens DD,Santoro AB,et al.Global Pharmacogenomics:Distribution of CYP3A5 Polymorphisms and Phenotypes in the Brazilian Population. PLo S One . 2014
  • 10Lesche D,Sigurdardottir V,Setoud R,et al.CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients. Therapeutic Drug Monitoring . 2014

同被引文献71

  • 1郑卫萍.肝肾联合移植术后排斥反应的发生率及其影响[J].实用器官移植电子杂志,2014,2(6). 被引量:3
  • 2张鑫,刘志红,郑敬民,陈朝红,唐政,陈劲松,黎磊石.肾移植患者他克莫司血药浓度的影响因素[J].肾脏病与透析肾移植杂志,2005,14(4):333-338. 被引量:21
  • 3王莉,文爱东,王禾,杨晓剑,陈苏宁,杨志福,王志睿,周敏.肝-胰-肾联合移植术后他克莫司的个体化用药[J].中国医院药学杂志,2007,27(6):796-798. 被引量:1
  • 4Lamba JK, Lin YS, Thummel K, et al. Common allelic variants ofcytochrome P4503A4 and their prevalence in different populations [J]. Pharmacogenetics, 2002,12(2) , 121-132.
  • 5Bakken GV, Molden E, Knutsen K, et al. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro [J]. Drug Metab Dispos,2012, 40(9) : 1778-1784.
  • 6Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4affects hepatic expression and response to statin drugs [ J ]. Pharmacogenomics, 2011,11 ( 4 ) : 274-286.
  • 7van der Weide K, van der Weide J. The influence of the CYP3A4- 22 polymorphism on serum concentration of quetiapine in psychiatric patients [ J]. J Chin Psychopharmacol, 2014,34(2) : 256-260.
  • 8Stockmann C, Fassl B, Gaedigk R, et al. Fluticasone propio- natepharmacogenetics: CYP3A4+ 22 polymorphism and pediatric asthmacontrol [ J ]. J Pediatr, 2013, 162 (6) : 1222-1227.
  • 9Langaee TY, Gong Y, Yarandi HN, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil [ J ]. Clin Pharmacol Ther, 2007, 81 (3) : 386-391.
  • 10Liu L, Yang L, Zhang YC, et al. Polymorphisms of drug- metabolizing enzymes genes in a Han Chinese population [ J ]. Zhonghua Yi Xue Za Zhi,2009, 89 (38) : 2675-2681.

引证文献6

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部